Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

Published:2017-11-14 Issue:11 Volume:14 Page:e1002435
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Mayer Kenneth H.^ORCID,Seaton Kelly E.^ORCID,Huang Yunda,Grunenberg Nicole^ORCID,Isaacs Abby,Allen Mary^ORCID,Ledgerwood Julie E.,Frank Ian^ORCID,Sobieszczyk Magdalena E.,Baden Lindsey R.,Rodriguez Benigno^ORCID,Van Tieu Hong,Tomaras Georgia D.,Deal Aaron,Goodman Derrick,Bailer Robert T.,Ferrari Guido,Jensen Ryan,Hural John,Graham Barney S.^ORCID,Mascola John R.,Corey Lawrence,Montefiori David C.^ORCID, ,

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference66 articles.

1. UNAIDS DATA 2017, published 20 July 2017. http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf

2. Prevention of HIV-1 infection with early antiretroviral therapy;MS Cohen;N Engl J Med,2011

3. UNAIDS. Prevention gap report 2016 [January 14, 2017]. http://www.unaids.org/en/resources/campaigns/prevention-gap.

4. Ending the HIV-AIDS Pandemic—Follow the Science;AS Fauci;N Engl J Med,2015

5. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies;P Hraber;J Virol,2014

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical trials and recent progress in HIV vaccine development;Functional & Integrative Genomics;2024-08-28

2. HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy;2024-07-12

3. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial;PLOS Medicine;2024-06-24

4. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives;Clinical Microbiology Reviews;2024-06-13

5. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention;Viruses;2024-06-04